790 A phase II study (TACTI-002) of eftilagimod alpha (a soluble LAG-3 protein) with pembrolizumab in PD-L1 unselected patients with metastatic non-small cell lung(NSCLC) or head and neck carcinoma(HNSCC)

• Enriqueta Felip,
• Christian Mueller,
• Martin Forster,
• Tim Clay,
• Matthew Krebs,
• Leora Horn,
• Frederic Triebel,
• Enric Carcereny,
• Margarita Majem,
• Bernard Doger,
• Julio Peguero,
• Pawan Bajaj,
• Patricia Roxburgh,
• Chrystelle Brignone

Affiliations

Enriqueta Felip

3Vall d’ Hebron Institute of Oncology, Barcelona, Spain

Christian Mueller

13Immutep, Berlin, Germany

Martin Forster

4University College London Hospitals NHS, London, UK

Tim Clay

6St John of God Subiaco Hospital, Perth, Australia

Matthew Krebs

1The Christie NHS Foundation Trust, Manchester, Manchester, UK

Leora Horn

9Vanderbilt University Medical Center (VU, Nashville, TN, USA

Frederic Triebel

13Immutep, Berlin, Germany

Enric Carcereny

7Institut Català d’Oncologia Badalona, Badalona, Spain

Margarita Majem

2Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

Bernard Doger

5Fundacion Jimenez Díaz, Madrid, Spain

Julio Peguero

8Oncology Consultants, P.A., Houston, Texas, USA

Pawan Bajaj

10Tasman Oncology, Queensland, Australia

Patricia Roxburgh

11Beatson West of Scotland Cancer Center, Glasgow, UK

Chrystelle Brignone

12Immutep S.A.S, Paris, France